(Q61371395)

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Anemia of chronic disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

A randomized controlled study of iron supplementation in patients treated with erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Iron therapy in the pediatric hemodialysis population

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Clinical practice. Nondiabetic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Assessment of iron status

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Acute-phase proteins and other systemic responses to inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Iron Deficiency and Erythropoiesis: New Diagnostic Approaches

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Regulation of iron metabolism in the acute-phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Detection of functional iron deficiency during erythropoietin treatment: a new approach

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Reticulocyte hemoglobin content to diagnose iron deficiency in children

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Hypochromic red cells and reticulocyte haemglobin content as markers of iron-deficient erythropoiesis in patients undergoing chronic haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

A randomized trial of iron deficiency testing strategies in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Clearance of red blood cells from the vascular bed of skeletal muscle with particular reference to reticulocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Assessment of iron deficiency in chronic hemodialysis patients: investigation of cutoff values for reticulocyte hemoglobin content

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021

Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1548-5315%2811%2970057-2

7 January 2021